急性失代偿性心力衰竭患者早期应用沙库巴曲缬沙坦的安全性评价

Safety Evaluation of Early Application of Sacubitril Valsartan in Patients with Acute Decompensated Heart Failure

目的:探讨急性失代偿性心力衰竭(ADHF)患者早期应用沙库巴曲缬沙坦的安全性。方法:选取2020年2月-2022年5月景德镇市第三人民医院收治的100例ADHF患者为研究对象,采用随机数字表法分为两组,各50例。两组入院后均给予常规治疗(抗心力衰竭、强心等)。对照组采用盐酸贝那普利片治疗,观察组采用沙库巴曲缬沙坦治疗,两组均连续治疗3个月。比较两组临床疗效、治疗前后心功能指标[左室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、室间隔厚度(IVS)、左房内径(LAD)]和血清学指标[超敏C反应蛋白(hs-CRP)、N末端脑钠肽前体(NT-proBNP)]、不良反应。结果:观察组治疗总有效率为92.00%,高于对照组的76.00%,差异有统计学意义(P<0.05)。治疗后,观察组心功能指标均优于对照组,差异均有统计学意义(P<0.05)。观察组治疗后hs-CRP、NT-proBNP水平均低于对照组,差异均有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:ADHF患者早期采用沙库巴曲缬沙坦能够提高临床疗效,改善患者心功能及血清学指标,安全性较好,值得临床推广应用。

Objective:To investigate the safety of early application of Sacubitril Valsartan in patients with acute decompensated heart failure(ADHF).Method:A total of 100 patients with ADHF who were admitted to the Third People’s Hospital of Jingdezhen from February 2020 to May 2022 were selected as the research objects and divided into two groups by random number table method,with 50 cases in each group.After admission,both groups were given conventional treatment(anti-heart failure,heart strengthening,etc.).The control group was treated with Benazepril Hydrochloride Tablets,and the observation group was treated with Sacubitril Valsartan.Both groups were treated continuously for 3 months.The clinical efficacy,before and after treatment of cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular endsystolic diameter(LVESD),interventricular septum thickness(IVS),left atrial diameter(LAD)]and serological indexes[high-sensitivity C reactive protein(hs-CRP),N-terminal probrain brain natriuretic peptide(NT-proBNP)]and adverse reactions were compared between the two groups.Result:The total effective rate in the observation group was 92.00%,which was higher than 76.00%in the control group,the difference was statistically significant(P<0.05).After treatment,the cardiac function indexes of the observation group were better than those of the control group,the differences were statistically significant(P<0.05).After treatment,the levels of hs-CRP,NT-proBNP in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Early application of Sacubitril Valsartan in patients with acute ADHF can improve the clinical efficacy,cardiac function and serological indexes,which is safe and worthy of clinical application.